慢性乙型肝炎患者肝脏脂肪变性与肝功能，炎症，糖脂代谢

StephenW

Eur Rev Med Pharmacol Sci. 2018 Sep;22(17):5640-5646. doi: 10.26355/eurrev_201809_15830.
Relations of hepatic steatosis with liver functions, inflammations, glucolipid metabolism in chronic hepatitis B patients.
Chen XL1, Han YD, Wang H.
Author information

1
    Ten Department of liver diseases, Sixth People's Hospital of Qingdao, Qingdao, Shandong, China. [email protected].

Abstract
OBJECTIVE:

To investigate the relations between the steatosis and liver functions, inflammations, and glucolipid metabolism in chronic hepatitis B patients.
PATIENTS AND METHODS:

A total of 144 chronic hepatitis B patients who were admitted to our hospital from January 2015 to April 2017 were selected and divided into the steatosis group (n=73) and the non-steatosis group (n=71) according to the detection of hepatic puncture biopsy. The general information of the patients including age, sex, and body mass index (BMI) was collected, and patients' liver functions, inflammations, and glucolipid metabolism indicators were determined and compared between the chronic hepatitis patients with steatosis and without steatosis. The chronic hepatitis patients with steatosis were further divided into the normal group and the abnormal group based on the level of C-reactive protein (CRP) (8 mg/L). Besides, according to the level of aspartate aminotransferase (AST), these patients were divided into the normal liver function group (AST<40 U/L) and the abnormal liver function group (AST>40 U/L), among whom the hepatic steatosis, glucolipid metabolism, and inflammations were compared. At the same time, the chronic hepatitis B patients with steatosis were divided into Group F1, Group F2, and Group F3 based on the fatty degeneration grade, the correlations of steatosis with inflammations, glucolipid metabolism, and liver functions were analyzed. At last, the regression analyses between steatosis and the inflammation grade, glucolipid metabolism and liver function indicators were conducted for Group F1, F2, and F3, respectively.
RESULTS:

In the chronic hepatitis B patients with steatosis, liver function indicators-alanine aminotransferase (ALT) and AST, levels of inflammatory factors-interleukin-2 (IL-2), IL-6 and CRP and glucolipid metabolism indicators-fasting blood glucose (FBG), 2h postprandial blood glucose (2h PBG), fasting insulin (FINS), triacylglycerol (TG), total cholesterol (TC), and low-density lipoprotein (LDL) were significantly higher than those without steatosis (p<0.05). The steatosis, liver functions, and glucolipid metabolism indicators were statistically different between patients in the normal inflammatory factor group and the abnormal inflammatory factor group (p<0.06). In addition, the liver function indicators (ALT and AST) and glucolipid metabolism indicators (FBG, 2h PBG, FINS, TG, TC, HDL, and LDL) in the abnormal group were statistically higher than those of normal inflammatory factor group (p<0.05). In the normal liver function group, the average fatty degeneration grade was statistically lower than that in the abnormal liver function group (p<0.05), and glucolipid metabolism indicators (FBG, 2h PBG, FINS, TG, TC, IL-2, IL-6, CRP, HDL, and LDL) were also markedly lower than those in the abnormal liver function group (p<0.05). The steatosis was positively correlated with relevant indicators, including the blood glucose indicator of FBG (r=0.509, p<0.05), liver function indicator of AST (r=0.602, p<0.05), the blood lipid indicator of TG (r=0.740, p<0.05), and the inflammatory factor of CRP (r=0.882, p<0.05), respectively. The disease course, BMI, 2h FBG, FINS, TG, TC, HDL, LDL, AST, ALT, and inflammatory factors of IL-2, IL-6, and CRP were involved in risk factors of steatosis (p<0.05).
CONCLUSIONS:

Our data demonstrates that the steatosis is correlated with liver functions, glucolipid metabolism and inflammation level in chronic hepatitis B patients, and the foregoing indicators can affect the disease development of chronic hepatitis B patients with steatosis.

PMID:
    30229840

StephenW

Eur Rev Med Pharmacol Sci。 2018年9月; 22（17）：5640-5646。 doi：10.26355 / eurrev_201809_15830。
慢性乙型肝炎患者肝脏脂肪变性与肝功能，炎症，糖脂代谢的关系。
陈XL1，韩YD，王H.
作者信息

1
    青岛市第六人民医院十大肝病科，山东青岛[email protected]。

抽象
目的：

探讨慢性乙型肝炎患者脂肪变性与肝功能，炎症和糖脂代谢的关系。
患者和方法：

选择2015年1月至2017年4月入住我院的144例慢性乙型肝炎患者，根据肝脏检测，分为脂肪变性组（n = 73）和非脂肪变性组（n = 71）。穿刺活检。收集患者的一般信息，包括年龄，性别和体重指数（BMI），并确定患者的肝功能，炎症和糖脂代谢指标，并对患有脂肪变性和无脂肪变性的慢性肝炎患者进行比较。根据C反应蛋白（CRP）（8mg / L）的水平，将患有脂肪变性的慢性肝炎患者进一步分为正常组和异常组。此外，根据天冬氨酸氨基转移酶（AST）的水平，将这些患者分为正常肝功能组（AST <40 U / L）和肝功能异常组（AST> 40 U / L），其中肝脏比较脂肪变性，糖脂代谢和炎症。同时，根据脂肪变性等级将慢性乙型肝炎脂肪症患者分为F1组，F2组和F3组，分析脂肪变性与炎症，糖脂代谢和肝功能的相关性。最后，分别对F1，F2和F3组进行了脂肪变性与炎症分级，糖脂代谢和肝功能指标的回归分析。
结果：

慢性乙型肝炎患者脂肪变性，肝功能指标 - 丙氨酸氨基转移酶（ALT）和AST，炎症因子 - 白细胞介素-2（IL-2），IL-6和CRP水平以及糖脂代谢指标 - 空腹血糖（FBG） ），餐后2h血糖（2h PBG），空腹胰岛素（FINS），三酰甘油（TG），总胆固醇（TC）和低密度脂蛋白（LDL）显着高于无脂肪变性患者（p <0.05）。正常炎症因子组和异常炎症因子组患者的脂肪变性，肝功能和糖脂代谢指标有统计学差异（p <0.06）。此外，异常组的肝功能指标（ALT和AST）和糖脂代谢指标（FBG，2h PBG，FINS，TG，TC，HDL和LDL）在统计学上高于正常炎症因子组（p < 0.05）。在正常肝功能组中，平均脂肪变性等级在统计学上低于异常肝功能组（p <0.05）和糖脂代谢指标（FBG，2h PBG，FINS，TG，TC，IL-2，IL） -6，CRP，HDL和LDL）也明显低于异常肝功能组（p <0.05）。脂肪变性与相关指标呈正相关，包括FBG血糖指标（r = 0.509，p <0.05），AST肝功能指标（r = 0.602，p <0.05），TG血脂指标（r =分别为0.740，p <0.05）和CRP的炎症因子（r = 0.882，p <0.05）。病程，BMI，2h FBG，FINS，TG，TC，HDL，LDL，AST，ALT，IL-2，IL-6和CRP的炎症因子参与脂肪变性的危险因素（p <0.05）。
结论：

我们的数据表明，脂肪变性与慢性乙型肝炎患者的肝功能，糖脂代谢和炎症水平相关，并且上述指标可以影响患有脂肪变性的慢性乙型肝炎患者的疾病发展。

结论：
    30229840